SNCE SCIENCE 37 HLDGS INC

Science 37 Quickly Impacts Performance in Under-Enrolling Clinical Trials

Science 37 Quickly Impacts Performance in Under-Enrolling Clinical Trials

Nearly 20 studies have successfully leveraged Science 37's medical and operational expertise to boost patient recruitment and enrollment activities

RESEARCH TRIANGLE PARK, N.C., June 27, 2024 (GLOBE NEWSWIRE) -- , a leader in enhancing patient access to clinical trials, has been added to over 20 studies that were lagging in recruitment, helping them to trend back towards their projected targets. Leveraging its proprietary and solutions, Science 37 efficiently identified, recruited, medically qualified, and enrolled patients without geographic restrictions.

"Enrollment delays can be costly and create immense pressure to deliver results,” commented Brian Smith, Senior VP of Project Delivery at Science 37. “Traditionally, study teams address this by starting up more sites and/or adding patient recruitment. However, today's study teams need solutions that expand patient access to their study regardless of their location. Science 37 provides access to patient populations that no traditional site can match."

Science 37 has successfully supplemented enrollment in a variety of studies, including Phase 2 through Phase 4 and Observational trials across therapeutic areas such as Hematology, Hepatology, Infectious Diseases, CNS, Oncology, and Rare Diseases like Primary Sclerosing Cholangitis and Fragile X Syndrome.

Science 37’s is available on a standalone basis to clinical research sponsors and CROs looking to enhance their patient enrollment efforts, or in combination with Science 37’s industry-leading flagship Virtual Site, the , as part of an accelerated patient access offering. For more information, please visit .

About Science 37

Science 37’s mission is to accelerate clinical research by enabling universal trial access for patients. Through our solutions; the Metasite™ and Patient Recruitment, we accelerate enrollment by expanding the reach of clinical trials to patients beyond the traditional site and rigorously qualifying patients prior to referring them to a traditional site. Our solutions are powered by a proprietary technology stack with in-house medical and operational experts that enhance quality through standardized workflows and best-in-class study orchestration. To learn more, visit , or email .

To view studies that Science 37 is actively recruiting for, please visit .

Media Inquiries

Science 37



EN
27/06/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on SCIENCE 37 HLDGS INC

 PRESS RELEASE

Science 37 Completes Second FDA Inspection as Enrollment Leader in Pha...

Science 37 Completes Second FDA Inspection as Enrollment Leader in Phase 3 Asthma Trial MORRISVILLE, N.C., April 08, 2025 (GLOBE NEWSWIRE) -- , a leader in enhancing patient access to clinical trials, today announced the successful completion of its second FDA inspection, reaffirming the quality of its Direct-to-Patient Site for clinical research. The inspection resulted in a No Action Indicated (NAI) categorization, with no objectionable conditions noted and no Form 483 issued. Led by Science 37's internal Quality Assurance & Compliance team, the inspection focused on the company’s role...

 PRESS RELEASE

Science 37 Appoints Tyler Van Horn as CEO to Lead Next Era of Patient-...

Science 37 Appoints Tyler Van Horn as CEO to Lead Next Era of Patient-Access Innovation Seasoned Strategist and Former Chief Commercial Officer Poised to Accelerate Access and Equity in Clinical Research MORRISVILLE, N.C., Jan. 14, 2025 (GLOBE NEWSWIRE) -- , a leader in enhancing patient access to clinical trials, announces the appointment of Tyler Van Horn as Chief Executive Officer. Formerly the company’s Chief Commercial Officer, Van Horn’s appointment follows his pivotal role in driving operational excellence and shaping the company’s strategic direction to better prioritize client ...

 PRESS RELEASE

Science 37 Nearly Doubles U.S. Enrollment for GSK Phase 3 Rare Disease...

Science 37 Nearly Doubles U.S. Enrollment for GSK Phase 3 Rare Disease Trial MORRISVILLE, N.C., Nov. 21, 2024 (GLOBE NEWSWIRE) -- , a leader in enhancing patient access to clinical trials, was a key enrolling site for the primary completion of a Phase 3 rare disease trial sponsored by global biopharmaceutical company, . The hepatology study of an investigational medicine for cholestatic pruritus in primary biliary cholangitis (PBC) required 230 global participants, of which Science 37 was able to contribute almost half (17 - 47%) of the U.S. enrollment for the study. Recognizing that t...

 PRESS RELEASE

Science 37 Earns Frost & Sullivan’s 2024 Global Company of the Year Aw...

Science 37 Earns Frost & Sullivan’s 2024 Global Company of the Year Award for Decentralized Clinical Trials Top Honor Recognizes Science 37’s Visionary Innovation, Market-Leading Performance, and Unmatched Customer Care in the Decentralized Clinical Trials Industry MORRISVILLE, N.C., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Today, , a leader in enhancing patient access to clinical trials, announced that it has received Frost & Sullivan’s 2024 Global Company of the Year Award. Recognizing the market participant that exemplifies visionary innovation, market-leading performance, and unmatched cu...

 PRESS RELEASE

Science 37 Unveils New Corporate Headquarters in Research Triangle Par...

Science 37 Unveils New Corporate Headquarters in Research Triangle Park, NC 19,000-square-foot facility reflects the company’s recent growth and continued commitment to the region MORRISVILLE, N.C., Aug. 06, 2024 (GLOBE NEWSWIRE) -- , a leader in enhancing patient access to clinical trials, today announced the grand opening of its new, 19,000-square-foot corporate headquarters in Morrisville, North Carolina, in the heart of Research Triangle Park. The new, state-of-the-art facility, will serve as a hub for all Science 37 operations, enabling cross-functional teams with greater opportun...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch